Prospect Associates Ii L P - Net Worth and Insider Trading

Prospect Associates Ii L P Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Prospect Associates Ii L P owns 3 companies in total, including Hansen Medical Inc (HNSN) , Amicus Therapeutics Inc (FOLD) , and Vanda Pharmaceuticals Inc (VNDA) .

Click here to see the complete history of Prospect Associates Ii L P’s form 4 insider trades.

Insider Ownership Summary of Prospect Associates Ii L P

Ticker	Comapny	Transaction Date	Type of Owner
HNSN	Hansen Medical Inc	2007-11-02	other: Fallen
FOLD	Amicus Therapeutics Inc	2007-05-30	10 percent owner
VNDA	Vanda Pharmaceuticals Inc	2006-04-12	10 percent owner

Prospect Associates Ii L P Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Prospect Associates Ii L P Ownership Network

Ownership Network List of Prospect Associates Ii L P

No Data

Ownership Network Relation of Prospect Associates Ii L P

Prospect Associates Ii L P Owned Company Details

What does Hansen Medical Inc do?

Who are the key executives at Hansen Medical Inc?

Prospect Associates Ii L P is the other: Fallen of Hansen Medical Inc. Other key executives at Hansen Medical Inc include 10 percent owner Oracle Partners Lp , director & Interim CFO Christopher P. Lowe , and 10 percent owner Oracle Ten Fund Master, Lp .

Hansen Medical Inc (HNSN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Hansen Medical Inc (HNSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Hansen Medical Inc (HNSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Hansen Medical Inc (HNSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Hansen Medical Inc Insider Transactions

No Available Data

What does Amicus Therapeutics Inc do?

Who are the key executives at Amicus Therapeutics Inc?

Prospect Associates Ii L P is the 10 percent owner of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .

Amicus Therapeutics Inc (FOLD) Insider Trades Summary

Over the past 18 months, Prospect Associates Ii L P made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 351,367 shares made by John F Crowley , a net sale of 233,261 shares made by Bradley L Campbell , and a net sale of 95,000 shares made by Ellen Rosenberg .

In summary, during the past 3 months, insiders sold 22,500 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 22,500 shares. During the past 18 months, 822,412 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 822,412 shares.

Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amicus Therapeutics Inc Insider Transactions

No Available Data

What does Vanda Pharmaceuticals Inc do?

Who are the key executives at Vanda Pharmaceuticals Inc?

Prospect Associates Ii L P is the 10 percent owner of Vanda Pharmaceuticals Inc. Other key executives at Vanda Pharmaceuticals Inc include VP & Acting CFO & Treasurer Kevin Patrick Moran , director & Chief Executive Officer Mihael Hristos Polymeropoulos , and SVP & Chief Marketing Officer Joakim Wijkstrom .

Vanda Pharmaceuticals Inc (VNDA) Insider Trades Summary

Over the past 18 months, Prospect Associates Ii L P made no insider transaction in Vanda Pharmaceuticals Inc (VNDA). Other recent insider transactions involving Vanda Pharmaceuticals Inc (VNDA) include a net sale of 35,163 shares made by Kevin Patrick Moran , a net sale of 31,688 shares made by Timothy Williams , and a net sale of 20,451 shares made by Joakim Wijkstrom .

In summary, during the past 3 months, insiders sold 2,251 shares of Vanda Pharmaceuticals Inc (VNDA) in total and bought 0 shares, with a net sale of 2,251 shares. During the past 18 months, 166,385 shares of Vanda Pharmaceuticals Inc (VNDA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 166,385 shares.

Vanda Pharmaceuticals Inc (VNDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vanda Pharmaceuticals Inc Insider Transactions

No Available Data

Prospect Associates Ii L P Mailing Address

Above is the net worth, insider trading, and ownership report for Prospect Associates Ii L P. You might contact Prospect Associates Ii L P via mailing address: 435 Tasso Street, Suite 200, Palo Alto Ca 94301.

Discussions on Prospect Associates Ii L P

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.